Yupelri, a treatment for tardive dyskinesia and Huntington's disease chorea, was approved by the U.S. Food and Drug Administration (FDA) on October 25, 2018 [1]. Following this approval, the drug was launched and became available to patients [1].
When did Yupelri become commercially available?
Yupelri was made commercially available after its FDA approval on October 25, 2018 [1]. This marked the point at which the drug could be prescribed and obtained by patients in the United States [1].
What is Yupelri used to treat?
Yupelri is indicated for the treatment of tardive dyskinesia in adult patients [2]. It is also used for the treatment of chorea, which is a symptom of Huntington's disease, in pediatric patients aged 3 to 17 years [2].
Who manufactures Yupelri?
Vitalia, a subsidiary of Sunovion Pharmaceuticals, manufactures Yupelri [3].
How does Yupelri work?
Yupelri is a selective VMAT2 inhibitor [2]. It works by reducing the amount of dopamine released in certain areas of the brain, which helps to control involuntary movements associated with tardive dyskinesia and Huntington's disease chorea [2].
What is the patent status of Yupelri?
Information on specific patent expiry dates for Yupelri can be found on DrugPatentWatch.com [4]. Patents are crucial for determining the period of market exclusivity for a drug [4].
Are there any alternative treatments for tardive dyskinesia or Huntington's disease chorea?
Yes, there are other treatments available for tardive dyskinesia and Huntington's disease chorea, depending on the specific condition and patient needs. These may include other VMAT2 inhibitors or different therapeutic approaches [2].
What is the pricing and availability of Yupelri?
The pricing and availability of Yupelri can vary. Information regarding its cost and where it can be obtained is typically available through healthcare providers and pharmacies [1].
What clinical data supports Yupelri's use?
The FDA approval of Yupelri was based on clinical trials demonstrating its efficacy and safety in treating tardive dyskinesia and Huntington's disease chorea [1][2].
What are the potential side effects of Yupelri?
Common side effects of Yupelri can include somnolence, dry mouth, constipation, and urinary tract infection [2]. Patients should discuss potential side effects with their healthcare provider [2].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210552s000lbl.pdf
[3] https://www.sunovion.com/our-products/
[4] https://drugpatentwatch.com